Assessment of Irisin, Adiponectin and Leptin Levels in Patients with Schizophrenia
dc.contributor.author | Erzin, Gamze | |
dc.contributor.author | Topcuoglu, Canan | |
dc.contributor.author | Kotan, Vahap O. | |
dc.contributor.author | Bayram, Senol | |
dc.contributor.author | Fountoulakis, Kostas | |
dc.contributor.pubmedID | 29219062 | en_US |
dc.date.accessioned | 2023-05-11T07:51:53Z | |
dc.date.available | 2023-05-11T07:51:53Z | |
dc.date.issued | 2018 | |
dc.description.abstract | Background: The patients with schizophrenia are at increased risk for problems regarding metabolic parameters due to their lifestyle and antipsychotic treatment. Objective: In this study, we aimed to evaluate the levels of adiponectin, leptin, irisin in patients with schizophrenia who were nondiabetic, nonobese and under antipsychotic treatment. Method: 5 ml sample of venous blood was collected from each participant. Blood cells were separated from the serum. The serum samples were stored in a -80 degrees C freezer. Biochemical analyses were performed on these samples. Adiponectin, leptin and irisin levels were measured by Enzyme Linked Immunosorbent Assay method. Results: The study included 88 subjects. Of them, 44 were patients with schizophrenia and 44 were healthy controls. There were no statistically significant results when the c-reactive protein, adiponectin, leptin and irisin levels were compared between the schizophrenia and the control group (p>0.05). Conclusion: In our study, adiponectin, leptin and irisin levels in patients with schizophrenia did not present a statistically significant difference from healthy controls. Therefore, there is a need for studies including more participants to investigate the level of irisin in patients with schizophrenia. | en_US |
dc.identifier.endpage | 169 | en_US |
dc.identifier.issn | 1871-5303 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.scopus | 2-s2.0-85043336170 | en_US |
dc.identifier.startpage | 163 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/8974 | |
dc.identifier.volume | 18 | en_US |
dc.identifier.wos | 000425041900008 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.2174/1871530318666171207142901 | en_US |
dc.relation.journal | ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Adipokine | en_US |
dc.subject | adiponectin | en_US |
dc.subject | antipsychotics | en_US |
dc.subject | irisin | en_US |
dc.subject | leptin | en_US |
dc.subject | metabolic syndrome | en_US |
dc.subject | schizophrenia | en_US |
dc.title | Assessment of Irisin, Adiponectin and Leptin Levels in Patients with Schizophrenia | en_US |
dc.type | article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: